Broad Clinical Labs

BURLINGTON, Mass.Nov. 6, 2024 /PRNewswire/ — Broad Clinical Labs (BCL) and the Genomes2Veterans (G2V) Research Program announced today that the Department of Veterans Affairs’ (VA)-funded Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS) clinical trial will use BCL’s Blended Genome-Exome (BGE) assay and analytical and interpretative pipelines to return genomic risk for prostate cancer to Veteran(s) who enroll in the trial, which has now started recruitment.

As healthcare shifts toward more personalized approaches, understanding individual risk is crucial for disease prevention. By leveraging biobank-linked healthcare systems like Veterans Affairs’ Million Veteran Program (MVP), researchers developed a new genomic risk model for prostate cancer called Prostate Cancer Integrated Risk Evaluation (P-CARE). The P-CARE model was developed using data from 585,418 male MVP participants, including 101,920 who identify as Black or African American. It combines genetic scores, family history, and genetic background to provide tailored risk assessments for prostate cancer. To ensure its accuracy, the model was validated in external datasets including those of the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) Consortium and from the NIH’s All of Us Research Program. The model is now being used in the ProGRESS clinical trial of precision prostate cancer screening.

Read the full article on prnewswire.com

Share this page on social